Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

Archives

Author Archives: MarkEdwards
Mar 2, 2022Mark EdwardsNews

Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

2 March 2022 ASX ANNOUNCEMENT Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial Medical Developments International Ltd (ASX: MVP) announces that the US Food and Drug Administration (FDA) has unconditionally lifted the agency’s clinical hold on Penthrox.  This means that MVP can immediately begin preparing for its Phase III US […]

Read more
Feb 25, 2022Mark EdwardsNews

MVP FY22 Half Year Results Investor Presentation

25 February 2022 ASX announcement Please refer to the following link for the MVP FY22 Half Year Results Investor Presentation slides – MVP FY22 HY Investor Presentation

Read more
Feb 24, 2022Mark EdwardsNews

MVP FY22 Half Year Report and Accounts

24 February 2022 ASX Announcement Medical Developments International Limited (ASX:MVP) today released its FY22 Half Year Report and Accounts. Please refer to the following link for a copy of the announcement – MVP FY22 Half Year Report and Accounts 

Read more
Nov 3, 2021Mark EdwardsNews

Company Chair and CEO Address to Shareholders

28 October 2021 ASX ANNOUNCEMENT Company Chair and CEO’s Address to Shareholders On Thursday 28 October 2021, MVP held its 18th Annual General Meeting.  The Company Chair and CEO address to shareholders is outlined in the following attachment – ASX Announcement – Address to Shareholders

Read more
Sep 27, 2021Mark EdwardsNews

FY21 Annual Report and AGM Notice of Meeting

27 September 2021 FY21 Annual Report and Annual General Meeting Notice of Meeting Medical Developments International (MVP) has released its FY21 Annual Report and also its AGM Notice of Meeting. Both can be found via the following links: MVP FY21 Annual Report Notice of AGM and Proxy Form

Read more
Aug 25, 2021Mark EdwardsNews

FY21 MVP Preliminary Final Report and Full Year Accounts

25 August 20201 ASX Announcement Medical Developments International Limited (ASX: MVP) today released its FY21 Preliminary Final Report and Full Year Accounts. Please refer to the following link for a copy of the announcement – MVP FY21 Preliminary Final Report

Read more
Jul 16, 2021Mark EdwardsNews

MVP Announces Outcome of Balance Sheet Review

16 July 2021 ASX ANNOUNCEMENT MVP Announces Outcome of Balance Sheet Review Medical Developments International Ltd (ASX: MVP) today announced that following its annual asset impairment review, it expects to recognise a non-cash charge of $7.5 – 8.5 million (after tax) within the Group’s 30 June 2021 accounts. MVP’s respiratory business has been adversely impacted […]

Read more
Mar 5, 2021Mark EdwardsNews

Appointment of Non-Executive Director – Mary Sontrop

5 March 2021 ASX ANNOUNCEMENT Appointment of Non-Executive Director – Mary Sontrop Medical Developments International Limited (ASX: MVP) is pleased to announce the appointment of Ms. Mary Sontrop as a Non-Executive Director of the Company with immediate effect. Mary has extensive international experience in the biopharmaceutical sector across manufacturing operations, quality, and business integration.  During […]

Read more
Feb 26, 2021Mark EdwardsNews

FY21 Half Year Report and Accounts

26 February 2021 ASX ANNOUNCEMENT Medical Developments International Limited (ASX:MVP) has today released its FY21 Half Year Report and Accounts. Please click on the following link to view the release – FY21 HY Report and Accounts  

Read more
Dec 14, 2020Mark EdwardsNews

MVP Completes $25m Placement

14 December 2020 ASX ANNOUNCEMENT Medical Developments completes a A$25 million placement to accelerate the commercialisation of Penthrox in European Markets Please refer to the attached for the full announcements – MVP – ASX Announcement – Completion of Placement Please also refer to the related Investor Presentation – MVP Investor Presentation

Read more
Page 1 of 9 : 123›»

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter